Tradestie Institutional Equity Comparison Engine

IBG vs IBO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

IBO Overall Edge

IBO Captures Institutional Edge (3โ€“0 Pillars ยท 7โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Impact BioMedical, Inc. (IBO) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, IBG trades at N/M Forward P/E with -187.6% operating margin (-38.6% YoY revenue) versus IBO at N/M Forward P/E and -12621.0% operating margin (+16.7% YoY). In options structure, IBG sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against IBO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner IBO
IBG N/M vs IBO N/M Fwd P/E
Growth & Margin Winner IBO
Op Margin -187.6% vs -12621.0% ยท YoY -38.6% vs +16.7%
Momentum & Technical Winner IBO
1Y -59.0% vs +862.8% ยท 52W Pos 2% vs 67%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
IBG NASDAQ
Innovation Beverage Group Limited Ordinary Shares
Beverages
$0.75
-4.1% 1D
Market Cap $3.3M
1M Return -7.43%
1Y Return -59.02%
Forward P/E N/M
Unified AI Score
45.2 / 100 HOLD
Tech 43.0 Fund 59.0 Flow 50.0 Mom 60.0
IBO NYSE American
Impact BioMedical, Inc.
Pharmaceutical Preparations
$4.91
-4.47% 1D
Market Cap $44.4M
1M Return +83.21%
1Y Return +862.75%
Forward P/E N/M
Unified AI Score
36.8 / 100 SELL
Tech 15.0 Fund 32.0 Flow 50.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: IBG -59.02% IBO +862.75% Spread: +921.77 pp (IBO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
IBG TTM Op. Margin: -187.6% IBO TTM Op. Margin: -12621.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IBG vs IBO. Trailing 12-month operating profitability (IBG -187.6% vs IBO -12621.0%) and valuation multiples (IBG N/M vs IBO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: IBG (2) vs IBO (7)
Institutional Metric IBG IBO Criterion Row Winner
Market Capitalization Scale $3.3M $44.4M Larger Scale IBO
Trailing P/E Ratio Valuation N/M 0.4x Lower Multiple IBO
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -38.6% +16.7% Higher Growth IBO
Operating Margin (TTM) Profitability -187.6% -12621.0% Higher Margin IBG
Net Profit Margin Profitability -223.4% 4247.4% Higher Margin IBO
Return on Equity (ROE) Capital Efficiency -159.3% 71.2% Higher ROE IBO
52-Week Range Position Momentum 2% ($1โ€“$6) 67% ($0โ€“$7) Stronger Trend IBO
Beta / 30D Volatility Risk Regime 1.10ฮฒ ยท 126% Vol -6.72ฮฒ ยท 120% Vol Lower Realized Risk IBO
Unified Institutional Score Composite Signal 45.2 / 100 (HOLD) 36.8 / 100 (SELL) Higher Composite IBG

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full IBG vs IBO Buy Guide
IBG UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live IBG Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
IBO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live IBO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither IBG nor IBO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.